Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.

Babette J A VerkouterenMarlies WakkeeAn K L ReynersPatty NelemansMaureen J B AartsEmőke RáczJorrit B TerraLot A DevrieseRobert-Jan AlersEllen KapiteijnRemco van DoornMarcel W BekkenkMarie G H C ReindersKlara Mosterd

Published in: British journal of cancer (2021)

Half of the aBCC patients progress within 1 year after the start of vismodegib treatment. More research is needed to investigate other treatment strategies after vismodegib progression and to evaluate long-term effects of repetitive vismodegib treatment.

Keyphrases

basal cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes